Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Polycythemia Vera 3Thrombocythemia, Essential 2Primary Myelofibrosis 2Myeloproliferative Disorders 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

fludarabine phosphate 18Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Busulfan 11Tacrolimus 10Mycophenolic Acid 10ruxolitinib 9fludarabine 7Methotrexate 6Cyclosporine 6Radiotherapy 5Aspirin 5Prednisone 4Melphalan 4Imatinib Mesylate 4Biopsy 4Antilymphocyte Serum 4peginterferon alfa-2a 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Specimen Handling 3Decitabine 3bomedemstat 2Thiotepa 2Surveys and Questionnaires 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Lenalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Polycythemia Vera × givinostat × Clear all
NCT01761968 2025-04-30

Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms

Italfarmaco

Phase 2 Active not recruiting
90 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00606307 2019-12-03

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Italfarmaco

Phase 2 Completed
29 enrolled 8 charts
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00928707 2019-10-31

PV

Italfarmaco

Phase 2 Completed
45 enrolled 10 charts
Myeloid

Polycythemia Vera

Data powered by HemOnc (CC BY 4.0) Colophon âš¡